



THE JOURNAL OF CLINICAL PSYCHIATRY

Supplementary Material

Article Title:

Interferon-Induced Depression in Chronic Hepatitis C: A Systematic Review and Meta-Analysis

Author(s):

Marc Udina, MD; Pere Castellví, PhD; José Moreno-España, MD; Ricard Navinés, MD, PhD; Manuel Valdés, MD, PhD; Xavier Forns, MD, PhD; Klaus Langohr, PhD; Ricard Solà, MD, PhD; Eduard Vieta, MD, PhD; and Rocío Martín-Santos, MD, PhD

DOI Number: 10.4088/JCP.12r07694

List of Supplementary Material for the article

1. [eAppendix 1](#) References of excluded articles

Disclaimer

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

eAppendix 1. References of excluded articles

A) Not VHC or not IFN

1. Maddock C, Baita A, Orrù MG, et al. Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: a prospective case series and a discussion of biological mechanisms. *J Psychopharmacol.* 2004;18(1):41-46.
2. Lieb K, Engelbrecht MA, Gut O, et al. Cognitive impairment in patients with chronic hepatitis treated with interferon alpha (IFNalpha): results from a prospective study. *Europ Psychiatry.* 2006;21(3):204-210.

B) Methodological

B1. Validated tools to assess depression not used

3. Renault PF, Hoofnagle JH, Park Y, et al. Psychiatric complications of long-term interferon alfa therapy. *Arch Intern Med.* 1987 Sep;147(9):1577-1580.
4. Braconier JH, Paulsen O, Engman K, Widell A. Combined alpha-interferon and ribavirin treatment in chronic hepatitis C: a pilot study. *Scand J Infect Dis.* 1995;27(4):325-329.
5. Chemello L, Cavalletto L, Noventa F, et al. Predictors of sustained response, relapse and no response in patients with chronic hepatitis C treated with interferon-alpha. *J Viral Hepat.* 1995;2(2):91-96.
6. Hakozaki Y, Shirahama T, Katou M, Nakagawa K, Oba K, Mitamura K. A controlled study to determine the optimal dose regimen of interferon-alpha 2b in chronic hepatitis C. *Am J Gastroenterol.* 1995;90(8):1246-1249.
7. Piazza M, Tosone G, Borgia G, et al. Long-term interferon-alpha therapy does not affect sex hormones in males with chronic hepatitis C. *J Interferon Cytokine Res.* 1997;17(9):525-529.
8. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. *N Engl J Med.* 1998 Nov 19;339(21):1493-1499.
9. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. *N Engl J Med.* 1998 Nov 19;339(21):1485-1492.
10. Lapiński TW, Prokopowicz D, Panasiuk A. Efficacy of interferon therapy on patients with HCV infection in dependence from the time of treatment. *Roczniki Akademii Medycznej W Białymstoku.* 1999;44:260-268.
11. Tripi S, Di Gaetano G, Soresi M, et al. Interferon-alpha alone versus interferon-alpha plus ribavirin in patients with chronic hepatitis C not responding to previous interferon-alpha treatment. *BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy.* 2000;13(4):299-304.
12. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. *N Engl J Med.* 2000 Dec 7;343(23):1666-1672.
13. Espinosa M, Rodriguez M, Martin-Malo A, et al. Interferon therapy in hemodialysis patients with chronic hepatitis C virus infection induces a high rate of long-term sustained virological and biochemical response. *Clinic Nephrol.* 2001;55(3):220-226.
14. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. *Lancet.* 2001 Sep 22;358(9286):958-965.
15. Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. *Hepatology.* 2002 Mar;35(3):704-708.
16. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med.* 2002;347(13):975-982.
17. Rockstroh JK, Mudar M, Lichtenfeld M, et al. Pilot study of interferon alpha high-dose induction therapy in combination with ribavirin for chronic hepatitis C in HIV-co-infected patients. *AIDS.* 2002;16(15):2083-2085.
18. August-Jörg BSE, Borovicka J, Dufour J-F, et al. Twenty-four vs. forty-eight weeks of re-therapy with interferon alpha 2b and ribavirin in interferon alpha monotherapy relapsers with chronic hepatitis C. *Swiss Med Wkly.* 2003;133(33-34):455-460.
19. Smallwood GA, Davis L, Connor K, Martinez E, Stieber AC, Heffron TG. Nonresponders of interferon/ribavirin treatment for recurrent hepatitis C following liver transplantation. *Transplant Proc.* 2003;35(4):1476-1477.
20. Suzuki E, Yoshida Y, Shibuya A, Miyaoka H. Nitric oxide involvement in depression during interferon-alpha therapy. *Int J Neuropsychopharmacol.* 2003;6(4):415-419.
21. Bagheri H, Fouladi A, Barange K, et al. Follow-up of adverse drug reactions from peginterferon alfa-2b-ribavirin therapy. *Pharmacotherapy.* 2004;24(11):1546-1553.
22. Getachew Y, Browning JD, Prebis M, Rogers T, Brown GR. Combination therapy for the treatment of hepatitis C in the veteran population: higher than expected rates of therapy discontinuation. *Aliment Pharmacol Ther.* 2004;20(6):629-636.
23. Rodriguez-Luna H, Khatib A, Sharma P, et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. *Transplantation.* 2004;77(2):190-194.
24. Strinko JM, Di Bisceglie AM, Hoffmann JA. A descriptive study of the relationship between mood disorders and hepatitis C treatment compliance: does nursing play a role? *Issues Ment Health Nurs.* 2004;25(7):715-722.
25. Sulkowski MS, Felizarta F, Smith C, et al. Daily versus thrice-weekly interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected persons: a multicenter randomized controlled trial. *J Acquir Immune Defic Syndr.* 2004;35(5):464-472.
26. Uchida M, Hamada A, Yamasaki M, Fujiyama S, Sasaki Y, Saito H. Assessment of adverse reactions and pharmacokinetics of ribavirin in combination with interferon alpha-2b in patients with chronic hepatitis C. *Drug Metab Pharmacokinet.* 2004;19(6):438-443.
27. Hilsabeck RC, Hassanein TI, Ziegler EA, Carlson MD, Perry W. Effect of interferon-alpha on cognitive functioning in patients with chronic hepatitis C. *JINS.* 2005;11(1):16-22.
28. Yu M-L, Dai C-Y, Lee L-P, et al. Outcome of chronic hepatitis C patients who required early termination of pegylated interferon-alpha plus ribavirin combination therapy. *AntivTher.* 2006;11(8):1015-1019.
29. Marcellin P, Lau GKK, Zeuzem S, et al. Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a. *Liver Int.* 2008;28(4):477-485.
30. Rustgi VK, Esposito S, Hamzeh FM, Shiffman ML. Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin. *Aliment Pharmacol Ther.* 2008;27(5):433-440.
31. Treloar C, Hopwood M. "Look, I'm fit, I'm positive and I'll be all right, thank you very much": coping with hepatitis C treatment and unrealistic optimism. *Psychol Heal Med.* 2008;13(3):360-366.
32. Dinges S, Morard I, Heim M, et al. Pegylated interferon-alpha2a/ribavirin treatment of recurrent hepatitis C after liver transplantation. *Transpl Infect Dis.* 2009;11(1):33-39.
33. Mori N, Imamura M, Kawakami Y, et al. Randomized trial of high-dose interferon-alpha-2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy. *J Med Vir* 2009;81(4):640-649.
34. Aziz S, Qamar R, Ahmed I, et al. Treatment profile of hepatitis C patients - a comparison of interferon alpha 2a and 2b treatment regimens. *JCPSP.* 2010;20(9):581-585.
35. Rotman Y, Borg BB, Soza A, et al. Low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response. *Aliment Pharmacol Ther.* 2010;31(9):1018-1027.
36. Sinakos E, Gigi E, Lalla T, et al. Health-related quality of life in Greek chronic hepatitis C patients during pegylated interferon and ribavirin treatment. *Hippokratia.* 2010;14(2):122-125.
37. Raghavan R, Ferlic-Stark L, Clarke C, Rungta M, Goodgame R. The Role of Patient Religiosity in the Evaluation and Treatment Outcomes for Chronic HCV Infection. *J Relig Health.* 2011.

B2. Validated tools to assess depression but depression not confirmed by a clinician (or not reported)

38. Hunt CM, Dominitz JA, Bute BP, Waters B, Blasi U, Williams DM. Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life. *Dig Dis Sci.* 1997;42(12):2482-2486.
39. Malaguarnera M, Di Fazio I, Restuccia S, Pistone G, Ferlito L, Rampello L. Interferon alpha-induced depression in chronic hepatitis C patients: comparison between different types of interferon alpha. *Neuropsychobiology.* 1998;37(2):93-97.
40. Juengling FD, Ebert D, Gut O, et al. Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. *Psychopharmacology.* 2000;152(4):383-389.
41. Scalori A, Apale P, Panizzuti F, et al. Depression during interferon therapy for chronic viral hepatitis: early identification of patients at risk by means of a computerized test. *Eur J Gastroenterol Hepatol.* 2000;12(5):505-509.
42. Kraus MR, Schäfer A, Csef H, Faller H, Mörk H, Scheurlen M. Compliance with therapy in patients with chronic hepatitis C: associations with psychiatric symptoms, interpersonal problems, and mode of acquisition. *Digestive Diseases and Sciences* 2001;46(10):2060-2065.

43. Maes M, Bonaccorso S, Marino V, et al. Treatment with interferon-alpha (IFN alpha) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFN alpha-induced depressive and anxiety symptoms and immune activation. *Mol Psychiatry*. 2001;6(4):475-480.
44. Malaguarnera M, Laurino A, Di Fazio I, et al. Neuropsychiatric effects and type of IFN-alpha in chronic hepatitis C. *J Interferon Cytokine Res. The Official Journal of the International Society for Interferon and Cytokine Research* 2001;21(5):273-278.
45. Bonaccorso S, Marino V, Puzella A, et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. *Journal of Clinical Psychopharmacology* 2002;22(1):86-90.
46. Fontana RJ, Schwartz SM, Gebremariam A, Lok ASF, Moyer CA. Emotional distress during interferon-alpha-2B and ribavirin treatment of chronic hepatitis C. *Psychosomatics*. 2002;43(5):378-385.
47. Kamei S, Sakai T, Matsuura M, et al. Alterations of quantitative EEG and mini-mental state examination in interferon-alpha-treated hepatitis C. *Europ Neurology*. 2002;48(2):102-107.
48. Koskinas J, Merkouraki P, Manesis E, Hadziyannis S. Assessment of depression in patients with chronic hepatitis: effect of interferon treatment. *Dig Dis*. 2002;20(3-4):284-288.
49. Lang J-P, Michel L, Halleguen O. [Treatment of affective disorder in hepatitis C. A prospective study in 50 patients]. *Ann Med Interne*. 2002;153(7 Suppl):2S22-30-22S22-30.
50. Dieperink E, Ho SB, Thuras P, Willenbring ML. A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. *Psychosomatics*. 2003;44(2):104-112.
51. Gohier B, Goeb J-L, Rannou-Dubas K, Fouchard I, Calès P, Garré J-B. Hepatitis C, alpha interferon, anxiety and depression disorders: a prospective study of 71 patients. *Biol Psychiatry*. 2003;4(3):115-118.
52. Kraus MR, Schäfer A, Faller H, Csef H, Scheurle M. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. *J Clin Psychiatry*. 2003;64(6):708-714.
53. Neri S, Pistone G, Saraceno B, Pennisi G, Luca S, Malaguarnera M. L-carnitine decreases severity and type of fatigue induced by interferon-alpha in the treatment of patients with hepatitis C. *Neuropsychobiology*. 2003;47(2):94-97.
54. Dieperink E, Ho SB, Tetrick L, Thuras P, Dua K, Willenbring ML. Suicidal ideation during interferon-alpha2b and ribavirin treatment of patients with chronic hepatitis C. *Gen Hosp Psychiatry*. 2004;26(3):237-240.
55. Maes M, Bonaccorso S. Lower activities of serum peptidases predict higher depressive and anxiety levels following interferon-alpha-based immunotherapy in patients with hepatitis C. *Acta Psychiatr Scand*. 2004;109(2):126-131.
56. Kraus MR, Schäfer A, Bentink T, et al. Sexual dysfunction in males with chronic hepatitis C and antiviral therapy: interferon-induced functional androgen deficiency or depression? *J Endocrinol*. 2005;185(2):345-352.
57. Kraus MR, Schäfer A, Wissmann S, Reimer P, Scheurle M. Neurocognitive changes in patients with hepatitis C receiving interferon alfa-2b and ribavirin. *Clin Pharmacol Ther*. 2005;77(1):90-100.
58. Kraus M-R, Schäfer A, Csef H, Scheurle M. Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C. *World J Gastroenterol*. 2005;11(12):1769-1774.
59. Raison CL, Borisov AS, Broadwell SD, et al. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. *J Clin Psychiatry*. 2005;66(1):41-48.
60. Raison CL, Broadwell SD, Borisov AS, et al. Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. *Brain Behav Immun*. 2005;19(1):23-27.
61. Reichenberg A, Gorman JM, Dieterich DT. Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study. *AIDS*. 2005;19 Suppl 3:S174-178-S174-178.
62. Scalori A, Pozzi M, Bellia V, et al. Interferon-induced depression: prevalence and management. *Dig Liver Dis* 2005 Feb;37(2):102-107.
63. Wichers MC, Koek GH, Robaey G, Verkerk R, Scharpé S, Maes M. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. *Mol Psychiatry*. 2005;10(6):538-544.
64. Yoshida K, Alagbe O, Wang X, et al. Promoter polymorphisms of the interferon-alpha receptor gene and development of Interferon-induced depressive symptoms in patients with chronic hepatitis C: preliminary findings. *Neuropsychobiology*. 2005;52(2):55-61.
65. Dan AA, Martin LM, Crone C, et al. Depression, anemia and health-related quality of life in chronic hepatitis C. *Journal of Hepatology* 2006;44(3):491-498.
66. Neri S, Pulvirenti D, Bertino G. Psychiatric symptoms induced by antiviral therapy in chronic hepatitis C: comparison between interferon-alpha-2a and interferon-alpha-2b. *Clin Drug Investig*. 2006;26(11):655-662.
67. Dan AA, Crone C, Wise TN, et al. Anger experiences among hepatitis C patients: relationship to depressive symptoms and health-related quality of life. *Psychosomatics*. 2007;48(3):223-229.
68. Kraus MR, Al-Taie O, Schäfer A, Pfersdorff M, Lesch K-P, Scheurle M. Serotonin-1A receptor gene HTR1A variation predicts interferon-induced depression in chronic hepatitis C. *Gastroenterology*. 2007;132(4):1279-1286.
69. Thein HH, Maruff P, Krahn MD, et al. Improved cognitive function as a consequence of hepatitis C virus treatment. *HIV Med*. 2007;8(8):520-528.
70. Wichers MC, Kenis G, Koek GH, Robaey G, Nicolson NA, Maes M. Interferon-alpha-induced depressive symptoms are related to changes in the cytokine network but not to cortisol. *J Psychosom Res*. 2007;62(2):207-214.
71. Zignego AL, Cozzi A, Carpenedo R, et al. HCV patients, psychopathology and tryptophan metabolism: analysis of the effects of pegylated interferon plus ribavirin treatment. *Dig Liver Dis*. 2007;39 Suppl 1:S107-111-S107-111.
72. Kraus MR, Schäfer A, Schöttker K, et al. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. *Gut*. 2008;57(4):531-536.
73. Martín-Santos R, Diez-Quevedo C, Castellví P, et al. De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C. *Aliment Pharmacol Ther*. 2008;27(3):257-265.
74. Bull SJ, Huezio-Diaz P, Binder EB, et al. Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. *Mol Psychiatry*. 2009;14(12):1095-1104.
75. Evon DM, Ramcharran D, Belle SH, Terrault NA, Fontana RJ, Fried MW. Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study. *Am J Gastroenterol*. 2009;104(12):2949-2958.
76. Falasca K, Mancino P, Ucciferri C, et al. Quality of life, depression, and cytokine patterns in patients with chronic hepatitis C treated with antiviral therapy. *Clin Inves Med*. 2009;32(3):E212-218-E212-218.
77. Schmidt F, Janssen G, Martin G, et al. Factors influencing long-term changes in mental health after interferon-alpha treatment of chronic hepatitis C. *Aliment Pharmacol Ther*. 2009;30(10):1049-1059.
78. Wobrock T, Mihm U, Löhr C, et al. Cognition in hepatitis C patients treated with pegylated interferon. *World J Biol Psychiatry*. 2009;10(4 Pt 3):819-826.
79. Krueger C, Hawkins K, Wong S, Enns MW, Minuk G, Rempel JD. Persistent pro-inflammatory cytokines following the initiation of pegylated IFN therapy in hepatitis C infection is associated with treatment-induced depression. *J Vir Hepat*. 2010.
80. Lang J-P, Melin P, Ouzan D, et al. Pegylated interferon-alpha2b plus ribavirin therapy in patients with hepatitis C and psychiatric disorders: results of a cohort study. *Antiv Ther*. 2010;15(4):599-606.
81. Phillips FH, Prebis M, Grumbeck C, Hale T, Cubillas R, Brown GR. Effects of recognizing depression with a standardized questionnaire (CES-D) versus patient reporting of depression after a single-standardized question on the outcomes of treatment for hepatitis C with pegylated interferon-a-2b and ribavirin. *Eur J Gastroenterol*. 2010;22(12):1435-1442.
82. Pierucci-Lagha A, Covault J, Bonkovsky HL, et al. A functional serotonin transporter gene polymorphism and depressive effects associated with interferon-alpha treatment. *Psychosomatics*. 2010;51(2):137-148.
83. Schäfer A, Scheurle M, Seufert J, et al. Platelet serotonin (5-HT) levels in interferon-treated patients with hepatitis C and its possible association with interferon-induced depression. *J Hepatol*. 2010;52(1):10-15.
84. Comai S, Cavalletto L, Chemello L, et al. Effects of PEG-interferon alpha plus ribavirin on tryptophan metabolism in patients with chronic hepatitis C. *Pharmacol Res*. 2011;63(1):85-92.
85. Felger JC, Alagbe O, Pace TWW, et al. Early activation of p38 mitogen activated protein kinase is associated with interferon-alpha-induced depression and fatigue. *Brain Behav Immun*. 2011.
86. Kenis G, Prickaerts J, van Os J, et al. Depressive symptoms following interferon-α therapy: mediated by immune-induced reductions in brain-derived neurotrophic factor? *Int J Neuropsychopharm*. 2011;14(2):247-253.
87. Smith AK, Simon JS, Gustafson EL, et al. Association of a polymorphism in the indoleamine- 2,3-dioxygenase gene and interferon-α-induced depression in patients with chronic hepatitis C. *Mol Psychiatry*. 2011.

C) Study design

88. Fontana RJ, Moyer CA, Sonnad S, et al. Comorbidities and quality of life in patients with interferon-refractory chronic hepatitis C. *Am J Gastroenterol*. 2001;96(1):170-178.

89. Nguyen HA, Miller AI, Dieperink E, et al. Spectrum of disease in U.S. veteran patients with hepatitis C. *Am J Gastroenterol*. 2002;97(7):1813-1820.
90. Lang JP, Halleguen O, Vecchionacci V, Doffoel M. [Reflections on the treatment of EDM in hepatitis C virus patients treated with interferon alpha from a retrospective survey concerning 29 patients]. *Encephale*. 2003;29(3 Pt 1):273-277.
91. Gochee PA, Powell EE, Purdie DM, et al. Association between apolipoprotein E epsilon4 and neuropsychiatric symptoms during interferon alpha treatment for chronic hepatitis C. *Psychosomatics*. 2004;45(1):49-57.
92. Gupta RK, Kumar R, Bassett M. Interferon-induced depressive illness in hep C patients responds to SSRI antidepressant treatments. *Neuropsychiatric Dis Treat*. 2006;2(3):355-358.
93. Carta MG, Hardoy MC, Garofalo A, et al. Association of chronic hepatitis C with major depressive disorders: irrespective of interferon-alpha therapy. *Clin Pract and Epidemiol Ment Health*. 2007;3:22-22.
94. Dollarhide AW, Loh C, Leckband SG, Endow-Eyer R, Robinson S, Meyer JM. Psychiatric comorbidity does not predict interferon treatment completion rates in hepatitis C seropositive veterans. *J Clin Gastroenterol*. 2007;41(3):322-328.
95. Evon DM, Verma A, Simpson K, Galanko JA, Dougherty KA, Fried MW. Psychiatric symptoms during interferon treatment for hepatitis C: experiences from a tertiary care hepatology centre. *Aliment Pharmacol Ther*. 2008;27(11):1071-1080.
96. Loftis JM, Huckans M, Ruimy S, Hinrichs DJ, Hauser P. Depressive symptoms in patients with chronic hepatitis C are correlated with elevated plasma levels of interleukin-1beta and tumor necrosis factor-alpha. *Neurosci Lett*. 2008;430(3):264-268.
97. Maru DS-R, Bruce RD, Basu S, Altice FL. Clinical outcomes of hepatitis C treatment in a prison setting: feasibility and effectiveness for challenging treatment populations. *Clin Infect Dis*. 2008;47(7):952-961.
98. Nelligan JA, Loftis JM, Matthews AM, Zucker BL, Linke AM, Hauser P. Depression comorbidity and antidepressant use in veterans with chronic hepatitis C: results from a retrospective chart review. *J Clin Psychiatry*. 2008;69(5):810-816.
99. Beste LA, Ioannou GN, Larson MS, Chapko M, Dominitz JA. Predictors of early treatment discontinuation among patients with genotype 1 hepatitis C and implications for viral eradication. *Clin Gastroenterol Hepatol*. 2010;8(11):972-978.
100. Butt AA, McGinnis KA, Skanderson M, Justice AC. Hepatitis C treatment completion rates in routine clinical care. *Liver Int*. 2010;30(2):240-250.
101. Lim C, Olson J, Zaman A, Phelps J, Ingram KD. Prevalence and impact of manic traits in depressed patients initiating interferon therapy for chronic hepatitis C infection. *J Clin Gastroenterol*. 2010;44(7):e141-146-e141-146.
102. Nguyen NH, VuTien P, Garcia RT, et al. Response to pegylated interferon and ribavirin in Asian American patients with chronic hepatitis C genotypes 1 vs 2/3 vs 6. *J Viral Hepat*. 2010;17(10):691-697.
103. Waizmann M, Ackermann G. High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once-daily ribavirin. *J of Subst Abuse Treat*. 2010;38(4):338-345.
104. Al-Hamoudi W, Mohamed H, Abaalkhail F, et al. Treatment of genotype 4 hepatitis C recurring after liver transplantation using a combination of pegylated interferon alfa-2a and ribavirin. *Dig Dis Sci*. 2011;56(6):1848-1852.
105. Galvão-de Almeida A, Quarantini LC, Sampaio AS, et al. Lack of association of indoleamine 2,3-dioxygenase polymorphisms with interferon-alpha-related depression in hepatitis C. *Brain Behav Immun*. 2011.
106. Oxenkrug G, Perianayagam M, Mikolich D, et al. Interferon-gamma (+874) T/A genotypes and risk of IFN-alpha-induced depression. *J Neural Transm*. 2011;118(2):271-274.

D) Therapeutic intervention

107. Lang JP, Meyer N, Doffoel M. [Benefits of a preventive psychiatric accompaniment in patients Hepatitis C Virus seropositive (HCV): prospective study concerning 39 patients]. *Encephale*. 2003;29(4 Pt 1):362-365.
108. Kraus MR, Schäfer A, Al-Taie O, Scheurlen M. Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. *J Viral Hepat*. 2005;12(1):96-100.
109. Schaefer M, Schwaiger M, Garkisch AS, et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. *J of Hepatol*. 2005;42(6):793-798.
110. Quarantini LC, Miranda-Scippa A, Schinoni MI, et al. Effect of amantadine on depressive symptoms in chronic hepatitis C patients treated with pegylated interferon: a randomized, controlled pilot study. *Clin Neuropharmacol*. 2006;29(3):138-143.
111. Gleason OC, Fucci JC, Yates WR, Philipson MA. Preventing relapse of major depression during interferon-alpha therapy for hepatitis C--A pilot study. *Dig Dis Sci*. 2007;52(10):2557-2563.
112. Kronenberger B, Berg T, Herrmann E, et al. Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trial. *Eur J Gastroenterol Hepatol*. 2007;19(8):639-646.
113. Martin KA, Krahn LE, Balan V, Rosati MJ. Modafinil's use in combating interferon-induced fatigue. *Dig Dis Sci*. 2007;52(4):893-896.
114. Morasco BJ, Rifal MA, Loftis JM, Indest DW, Moles JK, Hauser P. A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. *J Affect Disor*. 2007;103(1-3):83-90.
115. Raison CL, Woolwine BJ, Demetrashvili MF, et al. Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. *Aliment Pharmacol Ther*. 2007;25(10):1163-1174.
116. Klein MB, Cooper C, Brouillette M-J, et al. CTN-194 (PICCO): design of a trial of citalopram for the prevention of depression and its consequences in HIV-hepatitis C co-infected individuals initiating pegylated interferon/ribavirin therapy. *Contemp Clin Trials*. 2008;29(4):617-630.
117. Tarantino G, Basile V, Conca P, et al. Could the depression of obese patients suffering from chronic hepatitis C be temporarily improved? *J Viral Hepat*. 2008;15(9):646-650.
118. Furlanut M, Soardo G, Donnini D, Sechi L, Franceschi L. Fluoxetine disposition in patients with chronic hepatitis C treated with interferon- α . *Clin Pharmacokinetics*. 2010;49(11):767-772.
119. Morasco BJ, Loftis JM, Indest DW, et al. Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: a double-blind, placebo-controlled trial. *Psychosomatics*. 2010;51(5):401-408.
120. Neri S, Bertino G, Petralia A, et al. A multidisciplinary therapeutic approach for reducing the risk of psychiatric side effects in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin. *J Clin Gastroenterol*. 2010;44(9):e210-217-e210-217.
121. Diez-Quevedo C, Masnou H, Planas R, et al. Prophylactic treatment with escitalopram of pegylated interferon alfa-2a-induced depression in hepatitis C: a 12-week, randomized, double-blind, placebo-controlled trial. *J Clin Psychiatry*. 2011;72(4):522-528.

E) Sample description

122. Pariante CM, Orrù MG, Baita A, Farci MG, Carpiello B. Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders. *Lancet*. 1999;354(9173):131-132.
123. Mulder RT, Ang M, Chapman B, Ross A, Stevens IF, Edgar C. Interferon treatment is not associated with a worsening of psychiatric symptoms in patients with hepatitis C. *J Gastroenterol Hepatol*. 2000;15(3):300-303.
124. Cotler SJ, Ganger DR, Kaur S, et al. Daily interferon therapy for hepatitis C virus infection in liver transplant recipients. *Transplantation*. 2001;71(2):261-266.
125. Laguno M, Blanch J, Murillas J, et al. Depressive symptoms after initiation of interferon therapy in human immunodeficiency virus-infected patients with chronic hepatitis C. *Antiviral Ther*. 2004;9(6):905-909.
126. Maddock C, Landau S, Barry K, et al. Psychopathological symptoms during interferon-alpha and ribavirin treatment: effects on virologic response. *Mol Psychiatry*. 2005;10(4):332-333.
127. Guadagnino V, Trotta MP, Carioti J, Caroleo B, Antinori A. Does depression symptomatology affect medication compliance during the first weeks of anti-HCV therapy in intravenous drug users? *Dig Liver Dis*. 2006;38(2):119-124.
128. Bonkovsky HL, Snow KK, Malet PF, et al. Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. *J Hepatol*. 2007;46(3):420-431.
129. Fontana RJ, Bieliauskas LA, Lindsay KL, et al. Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C. *Hepatology*. 2007;45(5):1154-1163.
130. Fumaz CR, Muñoz-Moreno JA, Ballesteros AL, et al. Influence of the type of pegylated interferon on the onset of depressive and neuropsychiatric symptoms in HIV-HCV coinfecting patients. *AIDS Care*. 2007;19(1):138-145.
131. Posthouwer D, Fischer K, De Heusden N, Mauser-Bunschoten EP. Pegylated interferon and ribavirin combination therapy for chronic hepatitis C in patients with congenital bleeding disorders: a single-centre experience. *Haemophilia*. 2007;13(1):98-103.
132. Schaefer M, Hinzpeter A, Mohmand A, et al. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. *Hepatology*. 2007;46(4):991-998.
133. Dieperink E, Leskela J, Dieperink ME, Evans B, Thuras P, Ho SB. The effect of pegylated interferon-alpha2b and ribavirin on posttraumatic stress disorder symptoms. *Psychosomatics*. 2008;49(3):225-229.

134. Quereda C, Corral I, Moreno A, et al. Effect of treatment with efavirenz on neuropsychiatric adverse events of interferon in HIV/HCV-coinfected patients. *J Acquir Immun Defic Syndr*. 2008;49(1):61-63.
135. Alvarez-Uria G, Day JN, Nasir AJ, Russell SK, Vilar FJ. Factors associated with treatment failure of patients with psychiatric diseases and injecting drug users in the treatment of genotype 2 or 3 hepatitis C chronic infection. *Liver Intern*. 2009;29(7):1051-1055.
136. Ebner N, Wanner C, Winklbaur B, et al. Retention rate and side effects in a prospective trial on hepatitis C treatment with pegylated interferon alpha-2a and ribavirin in opioid-dependent patients. *Addiction Biol*. 2009;14(2):227-237.
137. Franssen Van De Putte DE, Fischer K, Posthouwer D, Van Erpecum K, Mauser-Bunschoten EP. Occurrence, course and risk factors of depression during antiviral treatment for chronic hepatitis C in patients with inherited bleeding disorders: a prospective study. *Haemophilia*. 2009;15(2):544-551.
138. Fontana RJ, Bieliauskas LA, Back-Madruga C, et al. Cognitive function does not worsen during long-term low-dose peginterferon therapy in patients with chronic hepatitis C. *Am J Gastroenterol*. 2010;105(7):1551-1560.
139. Holtzheimer PE, Veitengruber J, Wang CC, et al. Utility of the Beck Depression Inventory to screen for and track depression in injection drug users seeking hepatitis C treatment. *Gen Hosp Psych*. 2010;32(4):426-432.
140. Leutscher PDC, Lagging M, Buhl MR, et al. Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. *Hepatology*. 2010;52(2):430-435.
141. Franssen Van De Putte DE, Fischer K, Posthouwer D, Mauser-Bunschoten EP. The burden of HCV treatment in patients with inherited bleeding disorders. *Haemophilia*. 2011.
142. Sasadeusz JJ, Dore G, Kronborg I, Barton D, Yoshihara M, Weltman M. Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy. *Addiction*. 2011;106(5):977-984.

F) Overlap sample

143. Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alpha and ribavirin in psychiatric risk groups. *Hepatology*. 2003;37(2):443-451.
144. Loftis JM, Socherman RE, Howell CD, et al. Association of interferon-alpha-induced depression and improved treatment response in patients with hepatitis C. *Neurosci Lett*. 2004;365(2):87-91.
145. Loftis JM, Wall JM, Linardatos E, Benvenega S, Hauser P. A quantitative assessment of depression and thyroid dysfunction secondary to interferon-alpha therapy in patients with hepatitis C. *J Endocrinol Invest*. 2004;27(7):RC16-20-RC16-20.
146. Constant A, Castera L, Dantzer R, et al. Mood alterations during interferon-alpha therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. *J Clin Psychiatry*. 2005;66(8):1050-1057.
147. Majer M, Welberg LAM, Capuron L, Pagnoni G, Raison CL, Miller AH. IFN-alpha-induced motor slowing is associated with increased depression and fatigue in patients with chronic hepatitis C. *Brain Behav Immun*. 2008;22(6):870-880.
148. Raison CL, Borisov AS, Majer M, et al. Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. *Biol Psychiatry*. 2009;65(4):296-303.
149. Raison CL, Dantzer R, Kelley KW, et al. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. *Mol Psychiatry*. 2010;15(4):393-403.